ArticleNeuro-oncology advances

Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm.

Ayo Adeyemi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.